A popular weight-loss drug used by celebrities overseas has been approved by New Zealand’s medicine regulatory body, with its ...

Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half for even more patients that pay without insurance.

Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical ... Amycretin, a once-daily oral GLP-1/Amylin co-agonist, has shown competitive weight loss percentages in early trials.

In 2023, Khloe posted photos of ... shed the pounds. Novo Nordisk then developed Wegovy, which contains the same chemical but at higher doses specifically to aid weight loss.

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO ...

Novo Nordisk is betting on the future with a $2-billion deal to buy rights to a Chinese obesity drug. But investors remain unimpressed.

Also Read: Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug Novo Holdings CEO Kasim Kutay called 2024 “a very strong year” since the portfolio generated returns of 18%. That’s ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...